This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. By 2018, that share had fallen by about half.
SPAG, which serves global biopharma companies, health trade associations, and health provider systems, is also one of the most awarded agencies in the region having been named Global New PR Agency in 2015, Asia-Pacific Healthcare Agency of Year (2017 & 2019) at Sabre awards, and Large Agency of the Year in 2021 & 2022 by E4M (IPRCCA).
healthcare system over $800 billion annually. Collaboration across the entire ecosystem—from policymakers and regulators to healthcare providers to researchers—is critical for creating an environment where innovation can thrive. Ultimately, women’s healthcare needs are unique and demand tailored solutions.
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Following his graduate studies, Dr Hoppin was an Alexander von Humboldt Fellow at the Research Center Jülich, Center for Electronics in Germany from 2003 to 2005.
The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero. PNAS 2022, Vol.
Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcare providers and patients through product support, education, and training. As a leader in this market, VMS seeks constant improvement to their patient and healthcare provider experiences.
Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. In public speeches, she has suggested possibly expanding the program beyond Medicare, presumably to the commercial insurance market (covering 47% of all lives in the U.S.).
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content